|
Pharmacy and Therapeutics Committee
The Idaho Medicaid Pharmacy and Therapeutics Committee (P&T Committee) is comprised of Idaho health practitioners – physicians, physician assistant, pharmacists – who are committed to providing the right care at the right price. This committee meets four times per year to review clinical evidence. The P&T Committee makes recommendations to the Department of Health and Welfare regarding drug safety and efficacy as well as prior authorization requirements. Cost modeling analysis is done by the department twice per year – following the committee meetings in May and November.
Preferred Drug List (PDL)
General P&T Information
2012 Meeting Dates:
April 20
May 11
October 19
November 16
Voting Members
- Perry Brown, M.D. (Board Chairman, Boise, serving since January 2009)
- Catherine Hitt Piechowski, PharmD (Boise, serving since July 2008)
- Elaine Ladd, PharmD (Boise, serving since January 2010)
- John Mahan, M.D. (Boise, serving since July 2009)
- Dennis Tofteland, RPh (Meridian, serving since July 2008)
- Troy Geyman, MD (Bonners Ferry, serving since 2012)
- Jeffrey Johnson, PA (Meridian, serving since 2011)
Non-Voting Members
- Mark Turner, MD (Boise, serving since January 2009)
- Tamara Eide, PharmD (Medicaid Pharmacy Supervisor)
- Mark Johnston, RPh (Idaho Board of Pharmacy)
- Hamilton Warren-Sutton, MD (Boise, Mental Health Drug Adviser since November 2011)
Black = DERP Review
Green = Magellan/Provider Synergies
P&T Drug Review Schedule for 2012
|
P&T Meeting Dates
|
New Reviews
|
Re-Reviews
|
|
April 20, 2012 *
|
|
Angiotensin Modulators
Angiotensin Modulator Combinations
Beta Blockers
Calcium Channel Blockers
Lipotropics, Other
Lipotropics, Statins
Anticoagulants
Platelet Aggregation Inhibitors
PAH Agents, Oral
Androgenic Agents
BPH Treatments
Bladder Relaxant Preparations
Bone Resorption Suppression and Related Agents
Phosphate Binders
Hypoglycemics, Incretin Minetics/Enhancers
Hypoglycemics, Insulin
Hypoglycemics, Meglitinides
Hypoglycemics, TZD
Growth Hormone
Erythropoiesis Stimulating Proteins
Hepatitis C Agents
Pancreatic Enzymes
Proton Pump Inhibitors
|
|
May 11, 2012**
|
|
Analgesics, Narcotic long-acting
Analgesics, Narcotic short-acting
Opiate Dependence
Skeletal Muscle Relaxants
Antimigraine Agents
Antiemetics/Antivertigo Agents
Antibiotics, inhaled
Cephalosporins and Related Agents
Fluroquinolones, oral
Macrolides/Ketolides
Tetracyclines
Antibiotics, Topical
Antibiotics, Vaginal
Antifungals, Oral
Antifungals, Topical
Antiparasitics, Topical
Antivirals, Oral
Antivirals, Topical
Ulcerative Colitis Agents
Immunosuppressants
Multiple Sclerosis Agents
|
|
October 19,
2012 ***
|
|
Bronchodilators, Anticholinergic
Bronchodilators, Beta Agonist
Glucocorticoids, Inhaled
Leukotriene modifiers
Antihistamines, minimally sedating
Intranasal Rhinitis
Immunomodulators, Atopic Dermatitis
Cough and Cold, Cold
Cough and Cold, Narcotics
Cough and Cold Non-Narcotic
Otic Antibiotics
Epinephrine Self-injected
Ophthalmic Antiinflammatories
Ophthalmic Antibiotics
Ophthalmic Antibiotic/Steroid Combinations
Ophthalmics for Allergic Conjunctivitis
Ophthalmics, Glaucoma Agents
|
|
November 16, 2012****
|
|
Analgesics/Anesthetics, Topical
NSAIDs
Fibromyalgia Agents
Cytokine/CAM Agents
Antihyperurecemics, oral
Anticonvulsants
Antidepressants, other
Antidepressants, SSRIs
Atypical Antipsychotics
Typical Antipsychotics
Stimulants and Related Agents
Sedative Hypnotics
Alzheimer’s Agents
Antiparkinson’s Agents
|
*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 21, 2012. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the May meeting. These final decisions will be effective July 1, 2012.
**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 21, 2012. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective July 1, 2012.
***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 19, 2012. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the August meeting. These final decisions will be effective January 1, 2013.
****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 19, 2012. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective January 1, 2013.
|
|